Navigation Links
Adverse Effects in AIM-HIGH trial of Niaspan are Consistent With the Results Reported From HPS2-THRIVE Trial of ER Niacin Plus Laropiprant

OXFORD, England, March 25, 2013 /PRNewswire/ --

Senior researchers at Oxford University's Clinical Trial Service Unit welcomed today's statement by the Principal Investigators of the AIM-HIGH trial about the consistency of the adverse effects seen in the AIM-HIGH trial of extended-release niacin (Niaspan) with those reported from the HPS2-THRIVE trial of extended-release niacin given in combination with laropiprant (Tredaptive).

The findings of the HPS2-THRIVE trial of over 25,000 patients with pre-existing cardiovascular disease were presented by the Oxford University scientists at the American College of Cardiology (ACC) meeting in San Francisco on Saturday 9 March 2013. Adding extended-release niacin with laropiprant (which reduces flushing due to niacin) to effective statin-based cholesterol-lowering treatment failed to produce any clear benefits for these high risk patients. In addition, the expected side-effects of niacin were seen: skin rashes, gastro-intestinal (stomach) problems, complications with managing pre-existing diabetes and an increased risk of developing diabetes. Unexpectedly, however, there were also excesses of infections and bleeding (particularly in the gut and brain).

The very large randomised HPS2-THRIVE trial was able to show how frequent and how serious these expected and unexpected adverse effects were. On average, about 30 per 1000 patients treated for 4 years with the extended-release niacin/laropiprant combination suffered a serious adverse event - most of which required hospitalisation - due to the study treatment. But, since the HPS2-THRIVE trial tested the combination of extended-release niacin and laropiprant, it is not able to assess directly the separate effects of niacin and of laropiprant.

When the Oxford researchers first saw the preliminary results from the HPS2-THRIVE study, they contacted the Principal Investigators of the AIM-HIGH trial which had tested the effects of adding extended-release niacin (Niaspan) alone on top of statin-based treatment. The AIM-HIGH trial involved similar types of patients but it was much smaller, involving 3,400 patients treated for only about 3 years, and it was stopped prematurely in 2011 because of no apparent benefit. In response to the request by the Oxford researchers, the AIM-HIGH investigators looked specifically at all reports of infections and bleeding. They provided analyses of the effects of Niaspan on these outcomes, which they reported to be consistent (albeit based on smaller numbers) with the excesses seen in the HPS2-THRIVE trial.

"This is a crucial bit of the jigsaw," said Professor Rory Collins , CTSU Co-Director. "When we saw our results, the obvious thing to do was to ask the AIM-HIGH team to look at their data for these two unexpected adverse effects, bleeding and infection, since AIM-HIGH had tested niacin alone. We look forward to collaborating with the AIM-HIGH investigators in assessing these hazards further."

Principal Investigator Jane Armitage said: "The consistency of the AIM-HIGH results on infection and bleeding with the results of HPS2-THRIVE, along with clues from the older literature about the effects of niacin, make us reasonably confident that these are niacin effects. In the light of these findings, we firmly believe that the use of all niacin products used to treat lipids should now be reconsidered."

Following release of the HPS2-THRIVE results, the European Medicine Agency announced that it is to review niacin and related substances; see web link below: (

It is understood that the US FDA is also now considering a review of the safety of niacin. Niacin is much more widely used in the USA than in Europe. For example, it has been estimated that over 5 million prescriptions for Niaspan, costing over US$ 1 Billion, were issued in the USA last year.

SOURCE CTSU Oxford University
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Physician-Patient Alliance for Health & Safety: Monitoring Technology for PCA Pumps Can Prevent Adverse Events: So Why Are Hospitals Not Using It?
3. Velos, Inc. Introduces Mobile App for Oncology Adverse Events and Graft-Versus-Host Disease at 2012 ASCO Annual Meeting
4. Adverse Events Caused by Urinary Catheterization Endanger Patients Health Costing the US Health Care System Billions
5. The International Serious Adverse Event Consortium and UC San Diego To Collaborate On Research Into The Genetics Of Drug Induced Renal Injury
6. Top OTC Brand deploys Semantelli AETracker to monitor Adverse Events in Facebook
7. Class III Obese Patients Experience Adverse Events More Frequently Than the General Adverse Event Patient Population
8. Physician-Patient Alliance for Health & Safety: New Checklist Can Help Prevent 14,000 Opioid Adverse Events Annually
9. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
10. Statin Users Suffering from Side Effects Are in the Dark
11. Roskamp Institute Reports Beneficial Effects of Nutritional Supplementation with Anatabine in an Animal Model of Multiple Sclerosis
Post Your Comments:
(Date:11/26/2015)... --> --> ... find optimal contrast weighting of MRI for patients with ... a research agreement with SyntheticMR in order to use SyMRI ... is possible to generate multiple contrast images from a single ... left, thus making it possible to both fine tune images ...
(Date:11/26/2015)... 26, 2015 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ... which demands kidney transplantation is expected to boost the market ... for organ transplantation. --> 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ...
(Date:11/26/2015)... 26, 2015 ... "2016 Future Horizons and Growth Strategies ... Market: Supplier Shares, Country Segment Forecasts, Competitive ... offering. --> ) has ... Future Horizons and Growth Strategies in the ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... to discuss bioavailability and the need to integrate dose form selection in early ... with OBN, the membership organization supporting and bringing together the UK’s emerging life ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference ... Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held at ...
(Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, ... The new Q-Suite 6 platform is based on the latest Java Enterprise standards. By ... piece of software for many key components of the suite. Much of the suite ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... where preparing the perfect dish and pleasing the palates of attendees is of ... bringing a dish to a seasonal get-together, give these recipes a try this ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve the ... bather’s style and personality. From basic styles for the purist looking for simplicity ...
Breaking Medicine News(10 mins):